HistoSonics Announces Approval of its #HOPE4LIVER US Clinical Study

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

October 5, 2020

HistoSonics, developer of a non-invasive platform and novel sonic beam therapy, announced today that it has received approval of an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of its new platform technology, which is designed to use the science of histotripsy to mechanically destroy targeted liver tissue and tumors, from outside of the body.

HistoSonics said the study is a multi-center, open-label, and single-arm trial to evaluate the safety and efficacy in destroying liver tumors and will build upon the company’s first-in-man THERESA Study recently conducted in Barcelona, Spain. The company expects to begin enrolling patients in early 2021.

The number of patients in the US who have primary liver tumors has increased by 43% in the past 16 years and is expected to grow another 40% by 2030.  The liver is second only to lymph nodes as the most common site of metastatic tumors, those that spread from other organs and estimated to be present in up to 70% of patients with advanced disease from another site.

Patients eligible for the #HOPE4LIVER study will undergo non-invasive histotripsy in order to destroy up-to 3 primary or metastatic liver tumors in a single session and will be followed by the trial investigators to evaluate the safety and efficacy of their treatments.  The company intends to have up-to seven enrolling sites in the United States comprised of experienced multi-disciplinary liver specialists.  Successful completion of #HOPE4LIVER is expected to be used to support a US regulatory submission, and the company plans to immediately expand the use of its platform in additional solid tumors after completion of the US liver study.

“The approval of this study represents a significant milestone for our company and is the culmination of an incredible amount of work and dedication by a great number of people whose passion has been to make the science of histotripsy a reality for patients,” commented Mike Blue, President, and CEO of HistoSonics.  “I also want to thank all of our investigators and partners for their overwhelming response to this study and being true pioneers in their field.”

Dr. Joseph Amaral, FACS, Vice President of Medical Affairs, added, “Histotripsy is a uniquely differentiated treatment platform that has great promise to transform the care of patients.  We are humbled to have such exceptional investigators and leaders in the field involved in our first US study.  They, together with the patients who enroll in the study, will potentially pave the path to improved care in the future.”

The company also expects to initiate a similar European based clinical trial in early 2021.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.